170 related articles for article (PubMed ID: 38294575)
1. Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS
Kishnani PS; Shohet S; Raza S; Hummel N; Castelli JP; Sitaraman Das S; Jiang H; Kopiec A; Keyzor I; Hahn A
J Patient Rep Outcomes; 2024 Jan; 8(1):13. PubMed ID: 38294575
[TBL] [Abstract][Full Text] [Related]
2. Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease.
Lika A; Andrinopoulou ER; van der Beek NAME; Rizopoulos D; van der Ploeg AT; Kruijshaar ME
J Inherit Metab Dis; 2023 Jul; 46(4):595-604. PubMed ID: 36966448
[TBL] [Abstract][Full Text] [Related]
3. Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease.
Claeys KG; Kushlaf H; Raza S; Hummel N; Shohet S; Keyzor I; Kopiec A; Graham R; Fox B; Schoser B
Orphanet J Rare Dis; 2024 Apr; 19(1):154. PubMed ID: 38605392
[TBL] [Abstract][Full Text] [Related]
4. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
[TBL] [Abstract][Full Text] [Related]
5. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.
Yuan M; Andrinopoulou ER; Kruijshaar ME; Lika A; Harlaar L; van der Ploeg AT; Rizopoulos D; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):232. PubMed ID: 32883321
[TBL] [Abstract][Full Text] [Related]
6. Use of the patient-reported outcomes measurement information system (PROMIS®) to assess late-onset Pompe disease severity.
Harfouche M; Kishnani PS; Krusinska E; Gault J; Sitaraman S; Sowinski A; Katz I; Austin S; Goldstein M; Mulberg AE
J Patient Rep Outcomes; 2020 Oct; 4(1):83. PubMed ID: 33034771
[TBL] [Abstract][Full Text] [Related]
7. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
[TBL] [Abstract][Full Text] [Related]
8. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Jones HN; Kuchibhatla M; Crisp KD; Hobson Webb LD; Case L; Batten MT; Marcus JA; Kravitz RM; Kishnani PS
Mol Genet Metab; 2019 Aug; 127(4):346-354. PubMed ID: 31303277
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
Lachmann R; Schoser B
Orphanet J Rare Dis; 2013 Oct; 8():160. PubMed ID: 24119230
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
[TBL] [Abstract][Full Text] [Related]
12. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
[TBL] [Abstract][Full Text] [Related]
13. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
[TBL] [Abstract][Full Text] [Related]
14. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
Stepien KM; Hendriksz CJ; Roberts M; Sharma R
Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
16. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
Berger KI; Kanters S; Jansen JP; Stewart A; Sparks S; Haack KA; Bolzani A; Siliman G; Hamed A
J Neurol; 2019 Sep; 266(9):2312-2321. PubMed ID: 31187190
[TBL] [Abstract][Full Text] [Related]
17. Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.
Claeys KG; D'Hondt A; Fache L; Peers K; Depuydt CE
Cells; 2022 Jan; 11(3):. PubMed ID: 35159144
[TBL] [Abstract][Full Text] [Related]
18. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L; Hogrel JY; Perniconi B; Kruijshaar ME; Rizopoulos D; Taouagh N; Canal A; Brusse E; van Doorn PA; van der Ploeg AT; Laforêt P; van der Beek NAME
Neurology; 2019 Nov; 93(19):e1756-e1767. PubMed ID: 31619483
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
